# Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

> **NCT00002909** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** chemotherapy
- **DRUG:** oral sodium phenylbutyrate

## Key facts

- **NCT ID:** NCT00002909
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-02
- **Primary completion:** 2000-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002909, "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00002909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*